Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases.

Autor:	Gerolymatou N; N. Gerolymatou, MD, PhD, P.V. Voulgari, MD, PhD, Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina., Bakasis AD; A.D. Bakasis, MD, P.G. Vlachoyiannopoulos, MD, PhD, Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Voulgari PV; N. Gerolymatou, MD, PhD, P.V. Voulgari, MD, PhD, Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina; pvoulgar@uoi.gr., Vlachoyiannopoulos PG; A.D. Bakasis, MD, P.G. Vlachoyiannopoulos, MD, PhD, Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	The Journal of rheumatology [J Rheumatol] 2023 Aug; Vol. 50 (8), pp. 1078-1081. Date of Electronic Publication: 2022 Dec 15.
DOI:	10.3899/jrheum.221014
Abstrakt:	Objective: To describe data on the safety and efficacy of molnupiravir (MP) and nirmatrelvir/ritonavir (NM/R) in patients with systemic autoimmune rheumatic diseases (SARDs). Methods: Among patients with SARD being followed in 2 tertiary outpatient rheumatology clinics, we retrospectively identified those infected with SARS-CoV-2 between February and August 2022 who received MP or NM/R. Patients' medical files were reviewed for demographics and disease-related characteristics, as well as coronavirus disease (COVID-19) characteristics, including vaccination status, antiviral treatment, side effects, and COVID-19 outcomes. Results: Seventy-four patients with SARD (52 females) were identified who had been infected with SARS-CoV-2 and received MP (n = 26, 35.1%) or NM/R (n = 48, 64.9%). Most patients were vaccinated against SARS-CoV-2 (n = 62, 83.8%). Among frequently used regimens were glucocorticoids (n = 43, 58.1%), mycophenolate mofetil (n = 26, 35.1%), tumor necrosis factor inhibitors (n = 14, 18.9%), methotrexate (n = 13, 17.6%), and rituximab (n = 12, 16.2%). Common adverse events were reported only by 4 patients receiving NM/R (metallic taste, gastrointestinal upset, hypertension), not leading to drug discontinuation. During follow-up, all but 2 patients (n = 72, 97.3%) recovered at home without COVID-19-related complications. Nonetheless, we describe 2 presumptive cases of COVID-19 rebound who progressed to severe COVID-19. Conclusion: These data show a favorable outcome and acceptable safety profile of the 2 oral antiviral therapies MP and NM/R among a high-risk SARD population. However, cases of COVID-19 rebound are being increasingly identified. These findings call for continuous surveillance to capture the real-world efficacy and safety profiles in our subpopulations of interest. (Copyright © 2023 by the Journal of Rheumatology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu